News & Updates

Antibiotic and antiviral therapy in COVID-19 patients: Updates from ESCMID Global 2024

In COVID-19 patients, antibiotic therapy should be reserved only for suspected bacterial superinfections.

However, international data from over 1 million hospitalized COVID-19 patients across 65 countries showed that antibiotics were commonly prescribed empirically despite the low rates of reported bacterial co-infection.¹

New consensus guideline sets framework for obesity care in South and Southeast Asia

The increasing prevalence of obesity globally, including in South and Southeast Asia (S-SEA), has become a pressing public health concern, posing significant challenges to local economies, healthcare infrastructures, and individual well-being. [World Obesity Atlas 2022; https://www.worldobesityday.org/assets/downloads/World_Obesity_Atlas_2022_WEB.pdf]

Precise utilisation of triple therapy inhalers can reduce the burden of asthma in Singapore

On 16 April 2024, GSK organised the Trelegy Asthma: Release From Constriction seminar in Singapore. The event featured talks from distinguished experts, Associate Professor Loo Chian Min and Professor Simon Bowler who provided insights on the disease burden of asthma in Singapore and how a precision medicine approach with the single-inhaler triple therapy, Trelegy Ellipta, can improve lung function and symptom control in patients with uncontrolled asthma. The session was chaired by Dr Kenneth Chan.

Debunking the myths about DPP-4 inhibitors

Navigating the evolving landscape of diabetes management requires precise knowledge. In this exploration into the world of DPP-4 inhibitors (DPP4is), we aim to debunk prevalent myths and provide nuanced insights.

Product Highlight - MENQUADFI

Meningococcal group A, C, W & Y conjugate vaccine 0.5 mL solution for injection

Treatment advances in relapsed/refractory large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive subtype of non-Hodgkin’s lymphoma. Despite a high success rate associated with first-line immunochemotherapy, approximately 40% of patients relapse or demonstrate resistance to treatment, significantly reducing life expectancy.¹

Nirmatrelvir reduces the risk of long COVID

Post-COVID condition, also known as long COVID, is a serious public health problem affecting millions of people around the world.¹

Death, adverse health outcomes higher for COVID-19 than influenza after hospital admission

Robust evidence for fenofibrate in patients with metabolic syndrome on statins

Treating type 2 diabetes mellitus with G.R.A.C.E.

A challenging aspect of glycaemic control presents in patients diagnosed with early-onset type 2 diabetes mellitus (T2DM). Considering this challenge, how can effective management of glycaemic control be achieved in patients with uncontrolled T2DM who are hesitant to incorporate multiple oral antidiabetic drugs into their current regimen? In this case study, Dr Matthew Tan shared his clinical experience in managing a young adult patient with T2DM using GLYXAMBI^®, a fixed-dose combination of empagliflozin and linagliptin taken once daily. He demonstrated how applying the G.R.A.C.E. concept to the treatment improved the patient’s clinical outcome.

This advertorial is sponsored as an educational programme by Boehringer Ingelheim Singapore Pte. Ltd.